Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Marinus gets FDA rare pediatric disease designation for ganaxolone

Marinus Pharmaceuticals (NASDAQ:MRNS) received FDA rare pediatric disease designation for ganaxolone for the treatment of CDKL5 deficiency disorder (CDD). CDD is a rare refractive form of pediatric epilepsy caused by a...

July 31, 2020

Markets

Maxim ups Onconova Therapeutics PT to $3 from $1.25

Maxim Group raised its price target for Onconova Therapeutics (NASDAQ:ONTX) to $3 from $1.25 after the company announced that the required number of survival events for the pivotal Phase 3 INSPIRE study of IV rigosertib...

July 30, 2020

Markets

HCW starts Sierra Oncology at buy; PT $20

H.C. Wainwright launched coverage of Sierra Oncology (NASDAQ:SRRA) with a “buy” rating and $20 price target. The stock closed at $12.46 on July 29. Sierra Oncology is in the midst of a Phase 3 MOMENTUM study with its...

July 30, 2020

Developments

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharmaceuticals’ (NASDAQ:TTNP) CEO, Sunil Bhonsle, and Indegene VP of co-commercialization, Jamie Peck, provided additional information on their recently established Probuphine co-promotion partnership. In an...

July 29, 2020

Developments

Krystal Biotech initiates Phase 3 dystrophic epidermolysis bullosa trial

Krystal Biotech (NASDAQ:KRYS) initiated a Phase 3 clinical trial evaluating beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). DEB is a rare and severe monogenic skin disease with...

July 29, 2020

Developments

Regulus gets FDA orphan drug designation for polycystic kidney disease

Regulus Therapeutics’ (NASDAQ:RGLS) RGLS4236 received FDA orphan drug designation for the treatment of autosomal dominant polycystic kidney disease (ADPKD). ADPKD is caused by mutations in the PKD1 or PKD2 genes, and is...

July 29, 2020

Developments

Nabriva XENLETA gets European approval for community-acquired pneumonia

The EMA approved Nabriva Therapeutics’ (NASDAQ:NBRV) XENLETA for the treatment of community-acquired pneumonia. The approval is based on efficacy data from two Phase 3 clinical trials, both of which established XENLETA...

July 28, 2020

Developments

Protara gets FDA rare pediatric disease designation for lymphatic malformation

Protara Therapeutics’ (NASDAQ:TARA) TARA-002 received FDA rare pediatric disease designation for the treatment of lymphatic malformation. Lymphatic malformations are rare, typically congenital and result in the failure...

July 28, 2020

Markets

Dawson James cuts Soligenix to neutral; PT to $2 from $3

Dawson James Securities downgraded Soligenix (NASDAQ:SNGX) to “neutral” from “buy” and reduced its price target to $2 from $3, citing a model update for dilution. The stock closed at $2.13 on July 27. “We have updated...

July 28, 2020

Developments

Celsion randomizes first patients in Phase 1/2 ovarian cancer study

Celsion (NASDAQ:CLSN) randomized the first two patients in the Phase 2 portion of its Phase 1/2 study evaluating GEN-1 for the treatment of advanced ovarian cancer. GEN-1 is an interleukin-12 DNA plasmid vector...

July 27, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Markets

Maxim ups Heat Biologics PT to $5 from $2

Maxim Group raised its price target for Heat Biologics (NASDAQ:HTBX) to $5 from $2, citing the potential of the company’s vaccine platform to produce long-lasting cellular immunity against COVID-19. The stock closed at...

July 27, 2020

Subscribe